Jupiter Neurosciences partners with Catalent for Parkinson’s trial

JUPITER, FL - Jupiter Neurosciences, Inc. (NASDAQ: JUNS), a clinical-stage pharmaceutical company currently valued at $34.1 million, has announced a partnership with Catalent (NYSE:CTLT) Pharma Solutions, LLC for the production of JOTROL™ softgel capsules. According to InvestingPro analysis, the company’s stock is trading near its 52-week low of $1.01, suggesting significant market caution around its development programs. These capsules are to be used in a forthcoming Phase 2a clinical trial targeting Parkinson’s disease.

The agreement stipulates that Catalent will manufacture clinical batches of JOTROL™, a resveratrol-based therapeutic developed by Jupiter Neurosciences. The production under this partnership will adhere to current Good Manufacturing Practices (CGMP) and will include both active and placebo capsules for the study.

Christer Rosén, Chairman and CEO of Jupiter Neurosciences, emphasized the importance of collaborating with Catalent, citing their "industry-leading expertise in pharmaceutical manufacturing" and their ability to scale production efficiently. This step is deemed crucial for advancing JOTROL™ into clinical development for Parkinson’s disease.

JOTROL™ aims to address the limitations of resveratrol, a compound that has historically faced challenges with bioavailability and gastrointestinal side effects. The upcoming clinical trial will assess the safety, tolerability, and pharmacokinetics/pharmacodynamics (PK/PD) of JOTROL™ in Parkinson’s patients over three months.

With over 10 million individuals affected by Parkinson’s disease globally and a therapeutics market projected to surpass $14 billion by 2030, the demand for innovative treatments is high. Jupiter Neurosciences is actively seeking strategic partnerships to expedite the development of JOTROL™ for various neurodegenerative diseases, including Alzheimer’s.

Jupiter Neurosciences’ focus extends to treating neuroinflammation and central nervous system disorders. Their pipeline includes potential treatments for Alzheimer’s Disease, Parkinson’s Disease, Mucopolysaccharidoses Type I, Friedreich’s Ataxia, and MELAS.

The company’s previous Phase I study demonstrated that JOTROL™ achieves significantly higher bioavailability compared to earlier resveratrol products. This study’s results were published in reputable scientific journals in February 2022 and will be referenced in future JOTROL™ trials. With the next earnings report due on February 26, 2025, investors seeking detailed analysis of Jupiter’s development pipeline and financial metrics can access comprehensive research through InvestingPro’s advanced analytics platform.

This announcement is based on a press release statement.

In other recent news, Jupiter Neurosciences, Inc. has announced a strategic partnership with Zina Biopharmaceuticals, LLC to advance its Phase 2a clinical trial for Parkinson’s disease. The trial will focus on evaluating the safety and tolerability of JOTROL™, Jupiter’s patented resveratrol-based therapeutic platform. Additionally, Jupiter Neurosciences has revised the compensation agreement for its CFO, Saleem Elmasri, setting his monthly fee at $20,000 for the calendar year 2025.

The company has also entered into a strategic agreement with Dominant Treasure Health Company Limited, aiming to expand its product distribution in Southeast Asia. This involves a one-time payment of $2.3 million to Dominant Treasure, along with a success fee equivalent to 5% of any upfront or milestone payments received from distribution agreements negotiated by Dominant Treasure.

Moreover, Greenridge Capital has initiated coverage on Jupiter Neurosciences with a bullish Buy rating, expressing confidence in the potential of the company’s JOTROL platform. These are recent developments, and investors are encouraged to conduct their own comprehensive analysis.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.